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Um sistema de libertação de fármacos (DDS) pode transportar de forma precisa o 
fármaco para o sítio alvo,,i.e., directamente para a zona patológica ou ser 
administrado localmente. Uma vez no local de interesse, o DDS deve libertar o 
fármaco de forma controlada, de acordo com as necessidades específicas do 
paciente, garantindo in situ o tratamento desejado, sem efeitos nocivos sobre os 
tecidos saudáveis. 
A parte inorgânica do osso humano é composta principalmente por hidroxiapatite 
(Ca10(PO4)6(OH)2) (HAP). O quitosano (CH), um polímero natural e abundante. Para 
além de altamente biocompatíveis estes dois compostos são biodegradáveis, 
podendo ser utilizados em várias aplicações biomédicas (DDS, engenharia de 
tecidos, implantes, etc.). Além disso, as características de anfifilicidade e as boas 
propriedades mucoadesivas do quitosano, somadas à capacidade da HAP para 
absorver diferentes espécies químicas fazem destes compostos materiais desafiantes 
para um projecto de DDS. O presente trabalho aborda a combinação de HAP com CH 
para produção de um DDS. A dexametasona (DEX), que é um corticosteróide com 
acção anti-inflamatória, anti-neoplásica e efeitos imunossupressores, foi o fármaco 
modelo seleccionado. 
Neste trabalho produziram-se grânulos compósitos, com diferentes proporções de 
HAP e CH, por atomização de suspensões aquosas de HAP, quitosano e DEX. 
Utilizou-se glutaraldeído (GA) para reticular o CH e procedeu-se também à dupla 
atomização dos grânulos, uma técnica ainda não reportada na literatura. Os ensaios 
de libertação do fármaco foram efectuados por imersão dos grânulos carregadas com 
DEX em solução de fosfato tampão mantida a 37 ° C e sob agitação constante. 
Alíquotas de PBS foram retiradas após diferentes períodos de tempo e a sua 
concentração de fármaco avaliada por UV-Vis a λ = 241,5 nm. As características 
morfológicas e a composição de fases cristalinas dos grânulos atomizados foram 
avaliadas por micróscopia eletrónica de varrimento (SEM), por adsorção de N2 
usando a isotérmica de BET e por difração de raios-X (XRD). Os resultados obtidos 
mostraram que a variação da razão (HAP / CH) afectou a morfologia dos grânulos: 
quando a razão aumenta a morfologia dos grânulos evolui de esférica e rugosa para 
lisa e com concavidades. Por outro lado as características morfológicas dos grânulos 
duplamente atomizados indicam uma estrutura core-shell. 
No que se refere aos resultados de libertação de DEX, verificou-se que grânulos 
de composição diferente evidenciam perfis de libertação distintos: os grânulos 
reticulados com GA (0,2 %) apresentam uma curva de libertação mais lenta do que a 
observada para os grânulos com igual razão HAP/CH mas não modificados; quanto 
aos grânulos com dupla atomização, estes apresentam um padrão de libertação 
característico, com duplo patamar, em linha com a referida estrutura core-shell.   
Na tentativa de elucidar os mecanismos subjacentes à libertação de DEX, 
compararam-se os perfis medidos com diferentes modelos matemáticos. Verificou-se 
que o padrão de libertação da DEX pode ser adequadamente descrito pela equação 
de Peppas-Sahlin e de Weibull. Em conclusão, a reticulação e a engenharia de 
morfologia (estrutura core-shell) pela via da dupla atomização permitiram melhorar o 
perfil de libertação de DEX do DDS à base de grânulos compósitos de HAP/CH. 
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Drug Delivery System, Hydroxyapatite, Chitosan, Dexamethasone, Glutaraldehyde, 
Spray Drying, Core-Shell Structure, Drug Release, Peppas-Sahlin Model, Weibull 
Model 
A Drug Delivery System (DDS) may provide the precise transportation of the 
medical drug inside the patient’s body, directly to the pathological area or alternatively 
it may be also locally administrated. Once at the site of interest, the ideal DDS is 
expected to release the drug in a sustained manner according to the specific needs of 
the patient. As compared to other routes of drug administration, an appropriately 
designed DDS which active components are conveniently targeted should also ensure 
the desired in situ treatment without harmful effects of the drug over healthy tissues. 
The inorganic part of the human bone is mainly composed by hydroxyapatite 
(Ca10(PO4)6(OH)2) (HAP). Chitosan (CH), a natural polymer, is a linear glucose based 
polysaccharide. These two compounds are non-toxic, biodegradable and highly 
biocompatible and hence widely used for various biomedical applications (DDS, tissue 
engineering, implants, etc.). Moreover, some unique features including the 
amphiphilicity and good mucoadhesive properties of chitosan together with the ability 
of HAP to adsorb and then release different chemical species make these compounds 
challenging materials for DDS design. The present work addresses the combination of 
HAP and CH with a drug model aimed at engineering a DDS with a controlled drug 
release. Dexamethasone (DEX) is the drug model here selected. DEX is a 
corticosteroid with anti-inflammatory, antineoplastic and immunosuppressant effects, 
which is used for the treatment of various diseases like endocrine, dermatologic and 
neoplastic disorders and cancer among others.  
In the present research, composite granules with different ratios of HAP and CH 
components were produced by spray drying aqueous suspension of HAP, chitosan 
and DEX. To reduce polymer swelling, Glutaraldehyde (GA) was used to cross-link 
CH. Granules were also produced by a double spray drying technique, which so far 
has not been yet reported in the literature.  
The morphology and crystal phase composition of the produced granules were 
evaluated by scanning electron microscopy (SEM), N2 adsorption using the BET 
isotherm (BET), and X-ray diffraction (XRD). The obtained results showed that the 
variation of (HAP/CH) ratio affected the morphology of the granules as when that ratio 
increases the granules morphology changes from spherical with rough surface to a 
shape with concavities and smooth surface. Regarding the granules obtained by 
double spray drying, their morphological characteristics indicated that a core-shell 
structure was obtained.  
The drug release experiments were carried out by immersing the DEX loaded 
granules into phosphate buffer solution (PBS), kept at 37 °C under constant stirring. 
Aliquots of PBS were withdrawn after different times and their drug content evaluated 
by UV-Vis spectroscopy at λ= 241,5 nm. The results showed that granules with 
different composition could display different drug release patterns: HAP/CH granules 
cross-linked with GA (0,2 wt %) exhibit a more sustained drug release than granules 
with the same HAP/CH ratio without modification; as for double spray dried granules, 
a characteristic profile with a double plateau was observed, in line with a core-shell 
structure.  
Attempting to elucidate the mechanisms underlying DEX release, different 
mathematical models were compared with the measured release profiles. It was found 
that Peppas-Sahlin and Weibull equations are appropriate models for predicting the 
drug release from the produced granules. In conclusion, the cross-linking and 
morphology engineering (core-shell structure) via double spray drying allowed 
improving DEX release profile of HAP/CH DDSs.   
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1. Introduction 
 
One of the main ideas of the pharmacotherapy is to impact the affected part of the 
organism with a minimal negative effect to the whole body. A big number of drugs, like 
antibiotics, steroids, et al. can be dangerous if used in high dosages. The routes of 
medicines administration can be divided in four groups: enteral (delivered through the 
digestive tract), parenteral (bypassing the digestive system), topical (through the skin) and 
inhalation (via the respiratory tract). Different routes provide the possibility of regulating 
localisation, duration and velocity of medical effect. For example, the same drug 
substance taken orally or with an injection will start to impact in 2 − 4 hours or 10 − 20 
minutes respectively. A big disadvantage of the most peroral medication is the wide 
dissemination of the active components around the body. As a result higher dosages 
should be used to achieve the required therapeutic effect. The other limitations are that 
oral drugs can irritate the gastric mucosa or some of them can be decomposed by gastric 
juice. Since oral administrations, like all the enteral routes, have mainly a systemic action, 
the drug will also affect the uninjured parts of the body. However, the enteral 
administration is the most common in pharmaceutical therapy, due to its simplicity and the 
unassisted way of the method. 
The idea of the drug delivery systems (DDS) is the achievement of the required 
therapeutic effect. Such systems provide the precise transportation of the medicine inside 
the patient’s body directly to the pathological area, e.g. the injured organ or the nidus of 
inflammation. Due to their local application, DDS make it possible to use lower drug 
dosages. Properly chosen DDS with the controlled drug release allow having the 
prescribed concentration of the medicament during the therapy. Among all the other 
routes of medicine administration DDS is the most local and accurate way of medical 
treatment. The precise localisation of the active components minimizes the harmful effect.   
In recent years the number of studies of the DDS has increased rapidly. Currently 
many new systems are under medical testing. Depending on the properties of a drug 
substance, localization and type of disease different materials can be used as a drug 
carrier. There are systems based on polymers, lipids, protein/peptide nanotubes, metal 
nanostructures, composites, etc. (1).  
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Drug delivery systems provide a wide range of applications. One of the most 
perspective is the treatment of the different kinds of cancer. However, limited number of 
DDS at the pharmaceutical market is determined by the necessity of deep and precise 
analyses. The possible side effects of many DDS, as new medical substances, are still 
under on-going research. 
Design and construction of a new DDS requires approximately $ 20 – 50 million and 3 
– 5 years of work, sometimes clinical research can increase the time and final outlays. 
The world market of DDS shows continuous growth (Figure 1), thus in 2016 it should 
overcome $ 175 billion per year. The global market for drug delivery systems in 2010 was 
$ 131,6 billion (59 % contributed by the USA, 27 % – Europe, 14 % – the rest of the world) 
(2). 
 
Figure 1 – Global revenue of advanced drug delivery systems 2009 – 2016 (2). 
For aging people the increase of such bone diseases as osteoporosis, osteoarthritis 
and bone cancer is a serious problem. Osteoporosis (the disease of decreasing bone 
mass and density) is the reason of more than 1,3 million bone fractures each year. 
Especially hip and spine fractures are the most dangerous and harmful for patients. Very 
often bone disease becomes chronic and requires a long-term pharmacological therapy. 
Since bones are distributes throughout the body there are difficulties to maintain required 
concentration of the drug. Moreover, toxic-therapeutic window for bone treatment is 
usually narrow (3). 
Designing a good DDS for bone treatment the following obstacles should be taken 
into account: 
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 Drug carriers with large diameter (as liposomes for example) are not 
suitable for bone DDS, since the accessibility of large elements to the bone 
surface is limited. Bones possess membrane of lining cells, which functions as a 
marrow-blood barrier. 
 Bone mainly consists of mineral hydroxyapatite.  
 The efficiency of biomolecules with specific targeting affinity (e.g. enzymes, 
antigens) may be very low in mineralised surrounding (3). 
If a second surgery is not needed it is desirable for implanted devices to be removed 
device after all the drug has been released. Thus the application of bioresorbable material 
to design DDS for bone treatment is preferable (4). 
1.1. Objectives 
The main objective of this research is to develop a drug delivery system based on 
hydroxyapatite/chitosan particles, study the mechanisms underlying the DDS and 
compare different mathematical models for drug release prediction. 
1.2. Thesis structure 
This report consists of five chapters. Chapter 1 addresses the interest and objectives 
of the present study. There is a literature review about drug delivery systems, dwelling on 
drug delivery systems, applied requirements to them, materials the DDS are made from 
and techniques of their manufacture in Chapter 2. The problem formulation of this 
research is presented in Chapter 3. Chapter 4 describes materials and methods of the 
experimental procedure. The results and discussions are presented in Chapter 5. Finally 
the main conclusions and recommendations are summarized in Chapter 6.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
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2. Literature review 
2.1. Drug Delivery Systems (DDS) 
 
With the recent developments of medicine the old drug dosage forms became 
unsatisfactory to face the new challenging needs. The novel treatment approaches 
required new drug carriers, which could maintain a steady release of drug to the specific 
site of action. Therefore, drug delivery systems (DDSs) were developed. The first DDS 
originated in late 1930s, with a presentation at the Royal Society of medicine in London 
made by R. Deansby and A.S. Parkes. Their work was about sustained release of 
estrogen in several animals (5). 
Figure 2 illustrates the advantage of controlled drug release, which allows achieving a 
therapeutic effect in human body for a required time. Controlled released allows to obtain 
a more stable and predictable concentration of the drug in the organism within the 
therapeutic range. A DDS as opposed to one dosage of drug administration eliminates 
toxic concentrations. For an appropriate medical treatment the concentration of the drug 
should be maintained above ineffective, but below toxic level. 
 
Figure 2 – A schematic drawing illustrating the controlled drug release(adapted from (6)). 
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K.K. Jain (4) summarized the characteristics of an ideal drug delivery system as 
follows: 
 It should increase the bioavailability of the drug. 
 It should provide for controlled drug delivery. 
 It should transport the drug intact to the site of action while avoiding 
the nondiseased host tissues. 
 The product should be stable and delivery should be maintained 
under various physiological variables. 
  A high degree of drug dispersion. 
 It should be easy to administer to the patients. 
  It should be safe and reliable. 
  It should be cost-effective. 
 
While the ideal DDS is a goal to be pursued, the real DDSs are known to offer 
significant advantages over traditional systems though some disadvantages are still to be 
solved. Table 1 sums up the advantages and disadvantages of DDSs over traditional 
systems. 
 
Table 1 – Advantages and disadvantages of DDSs. 
Advantages of DDS DDS disadvantages 
Maintenance of optimal concentration of 
drug. 
Possibility of toxicity of the materials. 
Ability to deliver a drug selectively to a 
specific area. 
Harmful degradation products. 
 
Improving efficacy with less amount of drug Necessity of surgical intervention either on 
systems application or removal. 
Minimization of side effects. Patients discomfort with DDS device usage. 
Less frequent drug dosing. High cost of final product. 
 
According to literature Drug delivery systems can be divided in two main groups: time 
controlled (sustained) and spatially controlled (targeted) (3). 
Nanoparticles systems can improve the efficacy of drug delivery. One of the main 
advantages of nanoparticles is their large surface area. Nanoparticles tend to improve the 
efficiency and bioavailability of the drug by encapsulating high amount of medicine. The 
other outstanding advantage is the possibility of various modification of nanoparticle 
surface, which can be used for specific targeting to a tissue or cell for example (7). 
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Several types of nanoparticle-based DDSs are presented in Figure 3, i.e liposomes, 
dendrimers, ligands, magnetic particles. Most of these DDSs can be attributed to the 
targeted DDS. 
 
Figure 3 – Different types of nanotechnology-based drug delivery systems (8). 
In the case of polymeric micelles the therapeutic agent is loaded into the core, which 
is surrounded by copolymers forming an outer hydrophilic layer. The outer layer controls 
in vivo behaviour of DDS and the inner core of micelle structure responsible for drug 
loading (9). For example Wei Xu in (10) discussed application of polymeric micelles to 
protect poorly water-soluble drugs from gastrointestinal environment for controllable drug 
release in oral administration. Nowadays polymeric micelles system DDS becomes 
important for tumour diagnosis and therapy (9). 
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The advantage of liposomes is that their surface can be modified with various 
targeting ligands and attaching polyethylene glycol (PEG) units, which allows to get the so 
called “stealth liposome”. Stealth liposomes, due to their ability to avoid detection of an 
immune system, can circulate in the bloodstream during a prolonged time (8). The 
liposomes based DDS have been studied for the last 50 years. Liposomes are most 
commonly used as vehicles for drugs and antibodies targeted for the delivery of 
anticancer agents. Liposome DDSs allow to deliver various types of drugs, among which 
the following ones can be mentioned: anesthetics and anti-inflammatory drugs; the 
delivery of gene medicines; anti-cancer, anti-fungal and antibiotic drugs delivery (11). 
A large number of functionalizable groups make dendrimers very appropriate 
candidates for DDSs. Dendrimers are three-dimensional symmetric macromolecules. The 
tree- like structure of the reactive end groups of dendrimers are built around a central 
internal cavity molecule. Dendrimers-based DDSs are often used as chemotherapeutic 
agents for the treatment of cancer (8). Tailor-made surface of dendrimers allows wide 
opportunities for construction and tuning DDS with outstanding characteristics. Thus, 
Menjoge et al. studied dendrimers systems able to transport drug across human placenta, 
which opens a good perspectives for treatment selective treatment of pregnant women 
with minimizing harmful effect of the drug for the foetus (12-13).    (12) (13) 
Quantum dots are nanosized (1-10nm) semiconductors crystals able to fluorescence. 
Quantum dots provide a new class of nanosystems for cells/tumour labelling. Quantum 
dots cannot be used as a drug carrier, but their usage in combined DDSs enhances the 
diagnosis of tumour in cancer treatment (8).  Figure 4 illustrates quantum dots application 
for tumour imaging (14).  
Application of ferrofluids (colloidal solutions of iron oxide magnetic nanoparticles 
surrounded by a polymeric layer) in DDSs for example provides control of drug release by 
an external magnetic field (4,8). (8) (4)The same as quantum dots magnetic nanoparticle can be 
used in combined and complex structured DDSs. It was reported that magnetic 
nanoparticles DDSs have promising potential in gene therapy (15). 
The DDSs that allows achieving prolonged therapeutic effect by continuously drug 
releasing during a prolonged time after administration are called sustained DDSs . This 
type of DDS is designed to reduce dosing frequency and to increase the effectiveness of 
medicines thanks to drug localization (16). 
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Figure 4 – Tumour imaging in live animal (14). 
To get the maximal local drug delivery, the drug carriers should be able to contain a 
maximal amount of the drug. From this viewpoint, the advantage of using granules and 
porous materials, having high surface area, becomes obvious. Microspheres as DDSs can 
be used for a great number of applications: chemotherapy, cardiovascular disease 
therapy, hormone therapy, therapeutic protein delivery and vaccine development (17). 
Many of microspheres DDSs are sustained systems. 
Microspheres DDSs are presented by approximately spherical particles with the size 
in a range from 1 to 1000 µm. Microcapsules are the form of microsphere DDS (Figure 5). 
The difference of these systems is in drug location, thus microsphere represents matrix 
system with drug entrapped across it whole volume. In microcapsules drug is inside the 
system and the outer layer is presented by polymer coat. As it is seen from Figure 5 
microcapsules can be different than spherical geometry (18). 
 
Figure 5 – Structure of Microcapsules and microspheres used for drug delivery (18). 
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One of the most common materials for microspheres production are: biodegradable 
polymers (Chitosan, Alginic acid, Polyesters, etc.) (19). However, non-biodegradable 
polymers for different application can be used (Glycidyl methacrylate, Acrolein, etc.) (18). 
For bone treatment hydroxyapatite (HAP) microspheres are used. (20)  Figure 6 presents 
microstructured HAP microspheres produced by solid-in-water-in-oil (S/W/O) and studied 
by M.C. Sunny et.al. In his work M.C. Sunny used Chitosan (CH) as a binder for small 
HAP particles to form microspheres of desired size (20). 
 
Figure 6 – HAP-Chitosan microspheres (20). 
In the following paragraphs the methods of microsphere production and drug loading 
will be presented.  
2.1.1. Drug loading 
In general all the drug loading methods can be divided in two groups: 
 Incorporation methods – loading during the preparation of the particles (spray 
drying, freeze-drying, etc.).  
 Incubation methods – loading after the formation of the particles (soaking 
technique, vacuum adsorption, etc.) (21). 
The maximal drug loading can be achieved by incorporation methods (21). However, 
during spray drying the drug from the solution will be stored in the carriers in solid form. 
As a result the release will be more rapid as compared to the release when the drug is 
absorbed on the particles surface. All the appropriate techniques of the granule synthesis 
(spray drying, freeze-drying,) can be applied for the incorporation of the drug loading. The 
drug solution should be used as one of the initial components before the formation of the 
granules.  
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One of the simplest ways of incorporating the drug into the carrier is the soaking 
technique. When applying this method, the carriers are placed into the drug solution for a 
certain time, during which the drug is being absorbed from the solution. The drug content 
can be enhanced by increasing the drug concentration and the soaking time. The Vacuum 
adsorption is a more advanced method. The promotion of the drug adsorption is achieved 
by the initial location of the particles into the medium with reduced pressure. Thus, after 
the carriers are put into the solution, the adsorption goes faster (21). 
2.1.2. Drug release mechanisms 
The drug release from the chitosan carrier includes three processes; shown on Figure 
7; (release from the surface, diffusion from the swollen matrix, release due to erosion) 
Usually the release from the DDS cannot be described by only one process but in a 
varying degree by a combination of the processes shown on Figure 7. The more rapid 
process is the release from the particle surface, when the absorbed drug instantaneously 
dissolves in the surrounding medium. Such burst release was observed by He at al. (22) 
in their research chitosan granules loaded with different drugs (cimetidine, famotidine or 
nizatidine) were studied. It was shown that cross linking can reduce burst release. 
 
Figure 7 – Drug release from the micro particle (21). 
Drug release by diffusion is divided on three following steps: 
1. Water penetrates into particle, which starts swelling of polymer; 
2. Conversion polymer from glassy into rubbery state; 
3. Drug diffusion from swollen rubbery polymer (21). 
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It should be mentioned that for CH with higher molecular wait the release of a drug is 
slower, what can be explained by lower solubility and higher viscosity of high molecular 
weight CH in compare with low molecular weight CH (21). 
2.1.3. Modelling the drug release 
With the application of mathematical modelling it is possible to predict the release 
kinetics of the DDS, which is useful for the optimization of its design. Selecting the 
appropriate kinetic model for the drug delivery system is important for the identification of 
the parameters influencing the drug release. The methods used for studying the kinetics 
of the drug release can be divided into three groups (23): 
 Statistical methods (exploratory data analysis method, repeated measures 
design, multivariate approach, etc.); 
 Model based methods (zero order, first order, Higuchi, Korsmeyer-Peppas 
model, Hixson Crowell, Baker-Lonsdale model and Weibull model among 
others); 
 Model independent methods. 
In the present work Statistical methods and Model independent methods will not be 
discussed. The first due to its complexity. The second due to some limitations introduced 
by two factors (difference factor (f1) and a similarity factor (f2)) used in this method, which 
are sensitive to the number of dissolution points (23). 
Regarding model based methods, the main features of the most cited models will be 
reviewed in the next paragraphs. 
Higuchi model was the first mathematical model proposed in 1961 to describe the 
drug release for planar systems. Later it was generalised and adapted for different types 
of DDSs by the other scientists (23).The original equation has the view of Equation 1 (24-
25).    (24) (25) 
  
 
 √                                
(1) 
Where:     is amount of the drug released for the time t;   is surface area of the drug 
carrier;   is the diffusion coefficient of the drug;    and    are the initial concentration of 
the drug and the solubility of the drug in the matrix. Equation 1 can be simplified to the 
Equation 2: 
  
  
  √   
(2) 
Where:    is the total amount of the drug at time t=0 and   is the release rate constant 
showing the design variables of the DDS (geometry of the system: size, shape and 
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porosity of the carrier). The advantage of this model is in its simplicity: the amount of the 
drug released is proportional to the square root of the time. Nevertheless, before using 
Higuchi model the following assumptions should be considered:  
 the initial concentration of the drug should be higher than its solubility (     ); 
 the drug diffusion takes place in one dimension; 
 the diameter of the drug particles should be much smaller than the thickness of 
the system; 
 the swelling and dissolution of the matrix is negligible; 
 the diffusion of the drug is constant (24-26).   (24) (25) (26) 
Due to its simplicity Higuchi model can be applied for some systems to describe the 
release process in general. However, to attain more accurate results other kinetics models 
should be used. For the spherical matrix it is possible to apply the Baker–Lonsdale model 
(Equation 3), which was obtained from the Higuchi model. 
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It is obvious that Equation 3 represents a more specific system than the “general” 
Higuchi model. Thus, the impact of the spherical matrix radius    is already considered. 
Moreover, if the system is not homogeneous and has porosity or fractures the Baker–
Lonsdale model can be enhanced (Seki et al). (Equation 4) (26). 
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Where ε is the porosity of the matrix and τ is the tortuosity factor of the capillary 
system. 
Mathematical models help to optimize the interpretation and description of the drug 
release profile. Sometimes a big number of parameters and different physical and 
chemical mechanisms can influence the kinetic release, which makes it difficult or even 
impossible to obtain exact mathematical model. For a more general description of the 
drug release process Higuchi model, zero order model, Weibull model and Korsmeyer–
Peppas model can be used. (26)  
The zero order model is applied for the matrix tablets with low soluble drugs, osmotic 
systems, some transdermal systems, coated dosage forms and membrane systems. Zero 
order release kinetics is typical for the following types of drugs: heart and blood pressure 
maintenances, pain controllers, antidepressants, etc. (27) 
The Hixson-Crowell (Equation 5) model has several assumptions: 
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 The geometry of the particles is considered to be spherical and doesn't change 
with time 
 The particles remain intact and do not disintegrate into smaller fragments during 
dissolution 
For spherical geometry, the mathematical equation for this model is written as follows 
  
  
   (  
       
    
)
 
 
(5) 
The Weibull Equation 6 defines the cumulative fractional drug release expression as a 
function of time as follows: 
  
  
      (
 (      )
 
      
) 
(6) 
Because Weibull model is an empiric, it is criticized, since presents some deﬁciencies : 
• There is not any kinetic fundament and could only describe, but does not 
adequately characterize, the dissolution kinetic properties of the drug; 
• there is not any single parameter related with the intrinsic dissolution rate of the 
drug; 
• it is of limited use for establishing in vivo/in vitro correlations. 
 
Mathematical modelling has significant role in elucidating the important drug release 
mechanisms in DDSs. The transportation of drug inside DDS involves various physical 
and chemical phenomenon, making it difficult or sometimes even impossible to get the 
appropriate mathematical model for correct drug release description. Almost all 
mathematical models correspond to the known release mechanisms (diffusion-, swelling-, 
and erosion-controlled) (28). 
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2.2. Hydroxyapatite 
2.2.1. General information about hydroxyapatite (HAP)  
 
The human skeleton contains 20% of trabecular bone and 80% of cortical bone. 
Trabecular (cancellous) bone has a high porosity (50–90%) while cortical bone is a 
compact type of bone with 10 % porosity.  
The Human bone is a porous composite composed of an organic component 
(collagen) and an inorganic component (calcium phosphate, mainly in hydroxyapatite 
(HAP) form).The bone composition includes 60% of inorganic phase (mineral phase), 30% 
of organic matter, and 10% of water. The inorganic part is mainly represented by HAP. 
HAP crystals are small plates 2-3nm thick and tens of nanometres in length and width that 
precipitate onto the collagen fibres.  
The interaction between bone chemical components explains its unique mechanical 
properties, in which the compressive strength is originated from the rigid HAP, while 
collagen fibrils are capable of energy dissipation and impart the tensile properties. The 
Figure 8 illustrates the complex structure of the human bone (29). 
Figure 8 – Structure of human bone. 
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Hydroxyapatite (Ca10(PO4)6(OH)2) (HAP) based materials are widely used for 
biomedical applications, due to their chemical and structural similarity to the natural bone. 
In addition hydroxyapatite is a bioactive, biocompatible, bioresorbable and 
osteoconductive material with a good bone integration ability. HAP has been under study 
for the last sixty years and has been used in calcium phosphate cements, scaffolds for 
bone and dental replacement surgeries, drug delivery systems (DDS), etc.     
Depending on the Ca/P ratio there exist different modifications of calcium 
phosphates. This ratio can range from 0,5 to 2,0 determining the existence of different 
stoichiometric calcium phosphates: dicalcium phosphate dihydrate (brushite) – 1,0; 
octacalcium phosphate (OCP) – 1,33; α-tricalcium phosphate (α-TCP) – 1,5; β-tricalcium 
phosphate (β-TCP) – 1,5; hydroxyapatite – 1,67; tetracalcium phosphate – 2,0 and others. 
(30) As compared with HAP, β-TCP is more soluble; HAP has the best thermodynamic 
stability in physical environment (pH ≥ 5,4) among all the other calcium phosphates. (31)  
There is an opinion that the shape of HAP particles has a significant influence on the 
inflammatory risk. Therefore, the round regular-shaped particles are considered more 
preferable in comparison with the irregular-shaped ones (31). However, for the nanoscale 
particles, used for the drug delivery, this assumption can be questioned. 
As a drug delivery system (DDS) HAP can be used in the form of nanoparticles, in 
composite materials with different polymers and as a component of calcium phosphates 
cements or scaffolds.  
 
2.2.2. Synthesis of HAP 
 
One important objective has been to synthesise HAP as close as possible to the 
biological apatite. Nowadays it is possible to synthesise hydroxyapatite using various 
methods; precipitation from solutions, sol-gel method, solid state reactions, hydrothermal 
processing, electrospraying, flux cooling method, ultrasound and mechanochemical 
processing, etc. (32). Wet chemical syntheses methods are the cheapest and the 
simplest. However, among the disadvantages of these methods are the variability of 
morphology, crystallinity and size of hydroxyapatite particles (30). The final properties of 
HAP depend significantly on the shape, size, crystallinity and morphology of 
hydroxyapatite particles. It is possible to reach the required properties by choosing the 
synthesis technique and by varying its parameters. Thus, the increase of the sintering 
temperature of the particles synthesized by the sol-gel method, allows increasing the 
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crystallinity and the crystallite size of the final HAP particles (33). Even a small change of 
pH during the precipitation method affects significantly the particles’ size (34). Plasma 
spraying is among the most commonly used techniques for the commercial synthesis of 
HAP (30). The particle size and some advantages/disadvantages of different techniques 
are compared in the Table 2. 
The wet chemical methods (precipitation methods) are cheap and easy routes for 
HAP synthesis. However they have several drawbacks. Among them there are, first of all, 
the difficult reproducibility of the particle morphology and crystallinity. Secondly, the size of 
the particles is different and distributed non-uniformly. Formulas 7 and 8 are two common 
reaction described hydroxyapatite synthesis by wet chemical route (35): 
10Ca(NO3)2 + 6(NH4)2HPO4 + 8NH4OH → Ca10(PO4)6(OH)2 + 20NH4NO3 + 6H2O (7) 
10Ca(OH)2 + 6H3PO4 → Ca10(PO4 )6(OH)2 + 18H2O (8) 
  
In the precipitation method the particle morphology and the precipitated calcium 
phosphate phase depend on the pH during the reaction and on the Ca/P ratio of the 
reagents. The variation of these parameters can influence the final crystal structure that 
can be contaminated with different modifications of calcium phosphates (brushite, 
monetite, etc.) (33). 
The sol-gel is a two-phase technique in which the solution is converted to an 
amorphous gel which is dried afterwards. This method allows synthesising HAP particles 
of a nanometric size (35). Since the sol-gel technique provides a molecular-level mixing of 
calcium and phosphorus precursors, the homogeneity of the final HAP is high (33). 
Among the disadvantages of this method are the impurities and the poor crystallinity of the 
resulting product (35). 
Needle-like form particles with nanometric or micrometric sizes can be obtained using 
the hydrothermal technique. This method is based on the usage of high pressure and 
temperature. For example, hydroxyapatite particles can be synthesised by the reaction of 
calcium carbonate and diammonium hydrogen phosphate at re-crystallisation 
temperatures (200 – 300 °C) with the pressure of 1 – 2 kbar. Similarly to the previous two 
techniques, during the hydrothermal method it is difficult to regulate the size of HAP 
particles (33,35).   (33) (35) 
Nowadays plasma spraying is the most widespread technique for commercial 
production of HAP coatings.  
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Table 2 – Comparison of different synthesis methods of HAP (30). 
Method Particle size Comments 
wet chemical 
 
0,07–0,64 µm 
 
cheap, simple and slow; difficult to 
regulate particle size 
solid-state process 
 
0,1–1 µm 
 
difficult to regulate particle size and 
multiple phases seen in crystallisation 
hydrothermal 
 
1 µm 
 
difficult to regulate particle size 
mechanical–chemical 
 
0,13–0,14 µm 
 
simple but process requires strict 
adherence to recipe 
synthesis sol–gel nanosized subject to impurities 
chemical synthesis 50 nm subject to impurities 
sputter coating 0,5–3 µm 
cheap but line of sight technique and high 
temperatures introduce additional phases 
plasma spraying 30–200 µm 
uniform coating but surface coating 
amorphous 
 
2.2.3. HAP applications 
 
HAP has a wide application in scaffolds for bone tissue engineering, due to its 
bioactivity and osteoconductivity, HAP also induces osteogenesis. A good review of this 
subject can be found in the paper of K. Fox et al. (30) that covers the recent advances of 
nanophase hydroxyapatite applications. 
 Recently studies are directed on the possibility of combining HAP with different types 
of drug and materials for multipurpose applications, which can include cancer therapy, 
antimicrobial treatments, magnetic manipulation, osteoporosis treatment (30). HAP can be 
used in the production of nanoparticles, powders (36), drug delivery systems (37). 
HAP and related to it calcium phosphates have an excellent ability to bond to bone. 
Nano-hydrohyapatite is applied for bone augmentation, coating implants, as fillers in bone 
or teeth (30). The porous HAP-based scaffolds are used for the treatment of bone 
fractures, tumours and in the replacement of failed or loose joint. When HAP is used as a 
coating for implants it reduces aseptic loosening by improving bone apposition and 
osteoconductivity at the implant/bone interface.  
In 1970-s it was found that proteins could reversibly adsorb to HAP surface. HAP 
“history” as a material for drug delivery started can date back to this time. In spite of burst 
drug release, HAP surface can adsorb different medicaments that together with its 
compatibility inspired scientists to study HAP as a drug carrier material. HAP due to the 
negative charge of its core (-13.9 mV) can form a tight attraction with the positively 
Universidade de Aveiro                                                                         Literature review 
23 
 
charged chitosan. This interaction restrained the loaded drug, what is useful for prolonged 
drug release (30). HAP can be a drug carrier in different forms. The drug can be 
encapsulated inside HAP microspheres, loaded on the surface of HAP scaffolds or used 
in calcium phosphate cements (30). 
 Hap finds its main biomedical applications in scaffolds, dental implants, cements, 
drug delivery, coatings promoting bone ingrowth, bioactive glasses and etc. 
 
2.2.4. Debates about toxicity 
 
Although HAP has been studied for more than 50 years and used in numerous 
biomedical applications, there are still some disputes about the toxicity of hydroxyapatite 
nanoparticles. Thus, there were some ambiguities about cytotoxicity and genotoxicity of 
HAP nanoparticles. There is an opinion that nanoparticles can agglomerate inside the 
blood vessels similar to cholesterol. It is known that HAP can promote artery calcification 
as part of atherosclerosis. Therefore, when using HAP nanoparticles, possible 
atherosclerotic complications should be kept in mind. However, different clinical tests have 
not yet showed the real threat of HAP toxicity. Moreover, these nanoparticles were 
accepted on the US (FDA approval) and the EU (CE mark) markets (30). 
2.3. Chitosan 
2.3.1. General information about chitosan 
Chitosan is a natural linear glucose based polysaccharide. There are two main 
characteristics that impact chitosan properties: the degree of acetylation and the 
molecular weight. The deacetylation degree shows the percentage of D-glucosamine in 
the chitosan molecule. Thus, chitosan with 80% deacetylation degree contains on average 
80% of D-glucosamine residues and 20% of N-acetyl-D-glucosamine residues. Chitin is 
named chitosan in case the deacetylation degree is 60 – 100 % (Figure 9). The acid 
dissociation constant (pKa) and chitosan solubility can be modified by changing the 
degree of deacetylation. Due to the loss of charge chitosan will precipitate from the 
solution at neutral pH (38). It is found that chitosan can improve osteogenesis and 
angiogenic activity (39). The range of biological properties such as wound healing, 
osteogenesis enhancement and biodegradation are dependent on the viscosity of the 
chitosan solution. The viscosity can also be varied by changing the deacetylation degree 
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(31). Commercial chitosan is obtained from the shells of shrimp and other sea 
crustaceans. 
Chitosan is nontoxic, due to its degradation to the amino sugars, which are harmless 
and easily removable from the organism (21). 
 
Figure 9 – Chemical structures of chitin and chitosan (40). 
Thanks to the primary amino group chitosan has a cationic nature. This fact makes 
possible the interaction of chitosan with negativly charged surfaces (for example, 
proteins). As compared to many other natural polymers, chitosan is a unique one that has 
a positive charge. Due to the above mentioned properties and good mucoadhesive effect, 
there are numerous drug delivery systems based on chitosan (oral, ocular, nasal, vaginal, 
buccal, parenteral, intravesical and other DDS). Chitosan (CH) has a few disadvantages, 
among which are low mechanical properties, chemical and temperature instability (41). 
Although there are still a lot of on-going researches, the first DDS products have been 
already registered at the pharmaceutical market. Ciclopoli® containing a chitosan 
derivative (hydroxypropyl–chitosan) is one of them (41). 
To improve characteristic of chitosan and to decrease its swelling CH should be 
cross-linked. The crosslinking is formed by the no uniform length of chains and by terminal 
unities. This process can involve two CH unites of the same or different polymeric chain. 
In present work Glutaraldehyde (GA) was used as cross-ling agent. GA reacts with 
primary amine groups, what produces covalent glutaraldehyde crosslinking (42). 
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Figure 10 – Crosslinking of chitosan using glutaraldehyde (43). 
2.3.2. Methods for granules production  
 
There are several methods for producing CH granules. The 
coacervation/precipitation method (Figure 11(a)) is based on the property of chitosan to 
precipitate in alkaline solution. For the production of the particles the solution of chitosan 
is blown assisted by compressed air (to form the droplets) into the alkaline solution. After 
centrifugation and filtration the particles are washed with hot and cold water. To control 
the size of granules the pressure of the air and the diameter of the spray-nozzle can be 
varied (21). To impact the drug release different cross-linking agents for the particles 
hardening should be used (21). 
The ionic gelation method (Figure 11(b)) is based on the interaction between 
macromolecules with opposite charge. The chitosan solution under constant stirring is 
added drop wise to polyanionic solution of Tripolyphosphate (TPP). Due to the 
complexation interaction of the oppositely charged macromolecules, chitosan undergoes 
the ionic gelation and precipitates in the form of spherical particles (the range of size is 
from 500 to 710 µm) (21). 
 
Figure 11 – Layout of coacervation/precipitation method (a) and ionic gelation method (b) 
techniques (21). 
a b 
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The emulsion cross-linking method for the preparation of chitosan particulate 
systems is shown on Figure 12. This technique is based on the fact that chitosan amino 
groups are able to cross-link with aldehyde groups of the cross-linking agent (21). At first 
the water-in-oil emulsion of chitosan is prepared. Before being cross-linked with a proper 
agent, the aqueous droplets in the emulsion should be stabilized by the surfactant. After 
hardening the granules are filtered, washed and dried. This technique allows producing 
particles with the size range from 40 to 230 µm. The diameter of the final granules 
depends from the used cross-linking agent and can be controlled by the speed of stirring 
and varying the size of aqueous droplets (21). 
 
Figure 12 – Schematic representation of emulsion cross-linking method (21). 
The freeze-drying (Figure 13) method allows producing granules by freezing the 
sprayed suspension and then allows sublimating frozen water due to the pressure 
reduction. Owing to the sublimation of ice crystals the final granules will have porous 
structure.   
  
Figure 13 – Layout of freeze-drying technique. 
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The spray drying is a well-known and one of the widely-used techniques applied for 
the production of powders, granules or agglomerates from various mixtures and 
suspensions. The method is based on the drying of the sprayed suspension under a flow 
of hot air. The layout of the basic components used in the process of spray drying is 
represented on Figure 14. The advantage of this technique is that consistent sized 
particles can be produced from slurry or suspension by rapid drying. To regulate the size 
and the shape of the final product it is possible to use different kinds of spray nozzle, to 
vary temperature, the atomization pressure, the spray flow rate and the concentration of 
the components.  
 
Figure 14 - Layout of spray drying technique. 
Spray drying technique allows producing final particles with different morphology 
(powder, granules, capsules) depending on the composition of initial solution (Figure 15). 
 
Figure 15 – Schematically illustration of the final particle shape dependence from the initial 
suspension for spray drying (44). 
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Spray drying also allows using different type of nozzles with different diameters. In the 
Figure 16 is schematically presented granules produced by 2-fluid and 3-fluid nozzle. 
 
Some of the techniques applied for the synthesis of chitosan particles 
(coacervation/precipitation, ionic gelation, emulsion cross-linking methods) can be used 
for the production of composite granules, if hydroxyapatite is added to the initial 
components. However, spray drying and freeze-drying methods are preferable. 
2.3.3. Chitosan-based DDS.   
 
As it was already mentioned above CH is widely used in different fields of medicine 
and dentistry in different forms (Figure 17). Chitosan-based DDSs found the wide 
application for dental, buccal, gastrointenstinal, colon and gene delivery. Due to its 
muco/bioadhesive properties CH is an outstanding polymer for buccal delivery in form of 
tablets and films. The solution of CH can also be used for the buccal delivery of proteins, 
however to obtain prolonged release it is preferable to use CH in form of films or 
hydrogels. CH can be used as an effective material in different fields of dentistry, for 
example, in endodontics, CH can be used as dressing anti-inflammatory material for root 
canal. It was shown that CH stimulates fibroblastic cells, which decreases time of wound 
healing (45). 
 
Figure 16 – (a) Scheme of a 2-fluid and a 3-fluid nozzle (cross-section). (b) Schematic droplet 
structures produced by 2-fluid (left) and 3-fluid (right) nozzles (85). 
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Figure 17 – Different types of chitosan-based DDS (45). 
CH combines both bioadhesion and floating abillities that makes CH very promising 
material for gastroretentive DDSs. Chitosan-based delivery systems can provide ideal 
characteristics for slow drug release in the stomach (45). 
Recently it was founded that CH enhances the drug absorption trough mucosae 
without damaging the biological system during mucosal drug administration (ocular, nasal, 
buccal, gastro-enteric and vaginal-uterine therapy). It was shown that CH microparticles 
are very promising for vaccine delivery systems (21).  
There are works aimed to use CH-based DDSs for cancer therapy. Gadolinium 
neutron capture therapy is one of the novel types of cancer therapy. It is based on 
injection  specific Gd-contained compound into the area with tumour and following 
irradiation with thermal neutrons. This allows to achieve a high temperature inside cancer 
cells and destroy them. Gadopentetic acid-loaded CH nanoparticles were used as DDS 
for cancer therapy by this method (21).  
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Due to its biodegradable and biocompatible characteristics, together with the ability to 
form a complexes with DNA through electrostatic interactions CH is one of the most 
prominent material for gene delivery. Nowadays gene delivery allows treatment of genetic 
disorders, which were incurable some decades ago (21,45). (21) (45). 
2.4. Dexamethasone (DEX) 
2.4.1. DEX properties  
 
Dexamethasone (DEX) is a synthetic glucocorticoid class of steroid drugs which 
chemical structure is illustrated in Figure 18 and summary of characteristics are presented 
in Table 3.  It is frequently used as an anti-inflammatory drug. DEX is a synthetic version 
of a natural hormone produced by the adrenal glands. Since it is glucocorticosteroid, DEX 
has a wide range of actions on many parts of the body (46). Recent studies have 
demonstrated that DEX overcomes inflammatory effects (39) the in vitro use of 
dexamethasone promotes the formation of mineralized nodule of osteoblasts. DEX can 
also stimulate the proliferation of osteoprogenitor cells and their differentiation into 
osteoblasts (47). 
 
The main effects of dexamethasone are due to its anti-inflammatory properties and its 
ability to alter immune system responses. “Dexamethasone decreases inflammation by 
suppression of neutrophil migration, decreased production of inflammatory mediators and 
reversal of increased capillary permeability; suppresses normal immune response. 
Dexamethasone's mechanism of antiemetic activity is unknown” (48). It is also used in the 
treatment of certain blood cancers (such as leukemias) by making some cancerous white 
blood cells undergo self-destruction (46). 
Figure 18 – Chemical Structure of Dexamethasone (50). 
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Table 3 – Summary of DEX characteristics. (49-50) (49) (50) 
Molecular Formula C22H29FO5 
Molecular Weight 392.46 
Colour white to pale yellow 
Melting Point 255-261 °C 
Solubility in water (25 °C) 0.1mg/ml  
Solubility in ethanol, DMSO, DMF 25 mg/ml 
Biological half-life 36-54 hours 
Duration of metabolic effect 72 hours 
 
Dexamethasone is used in the treatment of various diseases (51): 
 Inflammatory disorders (rheumatoid arthritis) 
 As a part of cancer treatment therapy: 
o As a drug treatment: For example may help reduce swelling in the 
brain (caused by a brain tumour), spinal cord or bones. Used for 
leukaemia’s and lymphomas treatment along with chemotherapy 
o  To manage sides effect of the therapy. Nausea treating associated 
with chemotherapy; as palliation in leukaemia or lymphoma. 
 Addison’s disease (chronic endocrine system disorder of non-producing 
sufficient steroid hormones by the adrenal glands); 
 To prevent transplant rejection; 
 Alergic disorders (asthma); 
The side effects strongly depend from the treatment duration and used drug dosage. 
It is possible following common sides effects: increased appetite; trouble sleeping; excess 
fluid or swelling in the face, hands, or feet; weight gain; slowed wound healing; increased 
blood glucose levels. Less common side effects: headache; feeling dizzy; mood swings;  
low blood potassium level; muscle weakness; high blood pressure; feeling restless; skin 
rash; menstrual changes; bone or muscle pain and others. Among rare side effect the 
next could be diagnosed (probability is higher for lon-term use ): bleeding or ulcers in the 
digestive tract; vision changes; change in heart rhythm; congestive heart failure; allergic 
reaction, with symptoms like trouble breathing or swelling of the face, lips, tongue, or 
throat after injections of the drug; etc. (46,48, 50) (46) (48) 
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2.4.2. Drug Delivery Systems of DEX  
 
Nikolas J.S. London et al reported that DDS with DEX is one of the most recent 
additions to the macular edema treatment. Dexamethasone drug delivery systems with 
commercial name The Ozurdex® was approved by the United States Food and Drug 
Administration (FDA) for the treatment of macular edema. The Ozurdex® is biodegradable 
intravitreal implant loaded with 700 μg of DEX (52). 
Jun Sik Son et al studied (53) HAP scaffolds with the surface containing Dex-loaded 
PLGA microspheres (Figure 19). It was shown that the release after 2days of the non-
immobilized microspheres had an early burst of approximately 35% of the total DEX. The 
initial burst release was followed by a sustained release of the rest of the drug over the 
next 30 days. The profile of the drug release from microspheres immobilized on HAp 
scaffold surface was similar to profile of non-immobilized microspheres, just with lower 
amount of the released DEX. It was reported that kinetics of both drug releases followed 
an almost zero-order release. The first order release kinetic was explained due gradual 
depletion of DEX in the polymer. They have also concluded that DEX release took place 
by controlled molecular diffusion of DEX through the PLGA polymer either dissolution 
controlled or an erosion controlled mechanism (53). 
 
Figure 19 – HAP scaffold containing DEX-loaded PLGA microspheres (53). 
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3. Problem Formulation 
  
This research studies the drug release process from composite (HAP/CH) 
nanostructured granules. Granules loaded with DEX were prepared by spray drying 
technique. The effect of HAP/CH ratio on granules microstructure and drug release 
behaviour were analysed and investigated.  
In order to obtain a core-shell structure the granules were produced by two stage 
spray drying. First, granules from pure HAP loaded with DEX were spray dried. 
Afterwards, the granules were immersed into the solution of CH in acetic acid and the final 
suspension was spray dried. 
To reduce swelling of CH the cross-linking agent (GA) was used. The change of drug 
release behaviour was compared of non- and cross-linked DDS. 
The obtained results were compared with different mathematical models of drug 
release and the most adequate model was fitted for the DDS under study. 
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4. Experimental Procedure 
 
The experimental part of the research is divided into four sections: spray drying of 
granules with different (HAP/CH) ratio and loaded with Dexamethasone; double spray 
drying of non- and cross-linked granules; drug release from the produced granules; 
modelling of the drug release profile. 
The overall scheme of the experimental procedure is described in Figure 20. 
 
Figure 20 – Scheme of the experimental procedure. 
4.1. Materials 
 
The materials  used for spray driying were as follows: (1) Comercial suspension of 
Hydroxyapatite nanoparticles (5 wt% HAP nanoparticles, nanoXIM) from Fluidinova,; (2) 
Chitosan with a deacetylation degree ≥ 75% from Sigma-Aldrich, Iceland; (3) 
Dexamethasone (96% purity) from ACROS organics, USA; (4) Ammonia solution (98% 
purity)from Sigma-Aldrich, Germany; (5) Acetic acid solution (96% purity), from Sigma-
Aldrich, Germany; (6) Glutaraldehyde  (25% in H2O) from Sigma-Aldrich; (7) phosphate 
Preparation of the suspension with 
different HAP/CH ratio and DEX 
Spray drying 
Charaterization of the produced granules 
(SEM, XRD, FTIR, BET) 
Drug release experiment 
Modelling of the drug release profile  
Preparation of the HAP suspension with 
DEX 
Spray drying (1st stage) 
Preparation of the suspension of HAP 
granules loaded with DEX in CH solution  
Spray drying (2nd stage) 
Charaterization of produced granules 
(SEM, XRD, FTIR BET) 
Drug release experiment 
modelling of the drug release profile 
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buffer solution (PBS) 0,01M from Sigma-Aldrich; (8) Dialysis membranes, 12-14000 
Daltons from Medicell International Lt. 
4.2. Preparation methods 
4.2.1. Preparation of granules by single spray drying  
 
Suspensions with different HAP/CH ratio (Table 4) were prepared as follows: firstly, 
under constant stirring, chitosan was dissolved in the 2M solution of acetic acid. Then, 
HAP suspension (0,1 wt %; nanoXIM) with a pH stabilized at 6,5 with ammonia was 
added to the CH solution.  Finally DEX was added to the resulting suspension which was 
stirred and sonicated for 30 min until complete drug dissolution (0,1 mg/ml). The final 
suspension was spray dried using a laboratory spray dryer (Mini Spray Dryer Buchi-191, 
Figure 21(a)). The operational parameters of spray drying are presented in Table 5. 
Table 4 – Materials and reagents used for the production of composite granules. 
 Composition 
Materials and reagents* for 310 ml of 
suspension 
CH 
HAP (5% wt 
suspension) 
DEX 
GA      
(1% wt 
solution) 
Spray 
drying 
CH+DEX 0,625 g - 0,031 g - 
HAP:CH [1:2]+DEX 0,625 g 6,25 ml 0,031 g - 
HAP:CH [1:2]+DEX+GA 0,625 g 6,25 ml 0,031 g 0,125 ml 
HAP:CH [2:1]+DEX 0,156 g 6,25 ml 0,031 g - 
HAP+DEX - 6,25 ml 0,031 g - 
Double 
spray 
drying 
HAP:CH [1:2]+DEX 0,6250 g 6,25 ml 0,031 g - 
* - The solution of acetic acid was used to dissolve CH and the ammonia solution was used 
to regulate the pH of the suspensions 
 
4.2.2. Preparation of granules by double spray drying 
 
For double spray drying the granules were prepared in 2 stages: 
 The suspension of HAP (0,1 wt %) was stirred and sonicated with DEX (10 
wt % with respect  to HAP) for 30 min until complete drug dissolution. The resulting 
suspension was spray dried using the same functional parameters as mentioned in 
Table 5 and granules were collected. 
 The collected spray dried granules were then added to a solution of CH in 
acetic acid having a pH of 6,5. The quantities of granules and CH were adjusted 
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according to the desired (HAP/CH) ratios. The final suspension was stirred and 
then spray dried (Table 5).  
 
4.2.3. Preparation of cross linked granules 
 
To cross link the polymer a solution of glutaraldehyde was added to the HAP/CH 
suspension (0,2 wt % of glutaraldehyde with respect to CH) before the spray drying step.  
4.2.4. Spray drying step 
 
Spray drying is a well-known and widely-used technique for the production of 
powders, granules or agglomerates from various mixtures and suspensions. The method 
is based on the drying of a sprayed suspension under a flow of hot air. Spray dryer used 
in the present work and the layout of the basic components used in the process of spray 
drying are presented in Figure 21(a-b).  
 Figure 21 – (a) Mini Spray Dryer Buchi – 191; (b) – Schematic layout of the spray dryer 
(54): 1 – feeding pump; 2 – nozzle; 3 – atomization chamber; 4 – aspiration regulator; 5 – outlet 
temperature sensor; 6 – container for big particles; 7 – cyclone; 8 – container for spray dried 
granules. 
The advantage of this technique is that regularly sized particles or granules can be 
produced from slurries or suspensions by quick drying. The control of the size and shape 
Universidade de Aveiro                                                              Experimental Procedure 
 
42 
 
of the final particles or granules can be achieved by using different kinds of spray nozzles, 
by varying the temperature, the atomization pressure, the feeding rate and the 
concentration of the solution or suspension components. 
Table 5 – Operational parameters of spray drying 
Pumping  20%  
Aspiration  80% 
Spray drying temperature 180 °C  
Air flow velocity 500 l / h 
Nozzle type 2 fluid nozzle 
 
4.3. Materials characterization  
 
The characterization of the spray dried (HAP/CH) granules was carried out by the 
following methods: X-Ray diffraction (XRD), Scanning Electron Microscopy (SEM), N2 
adsorption with BET isotherms, Fourier Transform Infrared Spectroscopy (FTIR). The 
evaluation of the released DEX was made by Ultraviolet–visible (UV-vis) spectroscopy. 
4.3.1. X-Ray Diffraction analysis (XRD)  
 
X-Ray Diffraction analysis (XRD) is one of the diffraction methods used for studying 
the structure of matter. It is based on the phenomenon of X-ray diffraction by three-
dimensional crystal lattice. X-rays are generated in an X-ray tube; afterwards they are 
collimated and directed to the sample. The intensity of the reflected X-rays is recorded by 
the detector, which rotates together with the sample holder. The sample rotates at an 
angle θ, while the detector rotates at an angle of 2θ. According to Bragg’s law, after 
interaction with a sample the X-ray beam will be diffracted at a specific angle correlated to 
the periodicity and the arrangement of the crystal structure. 
XRD analysis (Rigaku PMG-VH) using monochromatic CuKα (1,5418Å) with radiation 
at 40kV was carried out to identify the crystal composition of the produced granules. The 
2θ scan range was in the interval 3-80° with a scanning speed of 3°/min.  
4.3.2. Scanning electron microscopy (SEM)  
 
The morphology (shape and size) of the granules was evaluated by scanning electron 
microscopy (SEM Hitachi S-4100). The samples of powder particles were glued to an 
sample holder with carbon tape and then coated with a conductive layer of carbon by 
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sputtering (EMITECH K950X) to be observed in SEM at 20-25 KV, using different 
magnifications. 
 In the scanning electron microscopy (SEM) (Figure 22) the focused beam of low-
energy electrons is used to raster along the sample surface. The image of the sample is 
generated by secondary electrons that are emitted from the surface after being excited by 
the electron beam. 
The interaction of a high-energy electron beam with the sample produces various 
secondary signals, many of which can be used in electron microscopy. Secondary 
electrons and backscattered electrons are used for sample imaging. Secondary electrons 
are relevant for analysing morphology and topography of specimens and backscattered 
electrons are used for contrast. Diffracted backscattered electrons are used for crystal 
structure determination and crystallographic orientation of the grains, from which the 
crystal structure consist. Emitted photons are used for elemental analysis. 
The layout of SEM basic elements is presented in Figure 22. On the top of the 
microscope there is an electron gun that produces the electron beam. The beam is 
focused by condenser lenses to a spot with a diameter of 0,5 to 5 nm. Before scanning 
the sample surface the beam passes through pairs of scanning coils of deflector plates in 
the electron column (where the beam is deflected either linearly or in a raster fashion). 
  
Figure 22 – Schematic layout of SEM (55). 
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SEM has a significant impact on different science fields: material science, medical 
science, biology, etc. The scanning electron microscopy provides information about 
microstructure (materials morphology, i.e. materials shape and size), composition and 
other properties of a sample with high resolution (55). 
 
4.3.3. Fourier Transform Infrared Spectroscopy (FTIR)  
 
The Fourier Transform Infrared Spectroscopy (FTIR) allows to detect the presence of 
chemical bonds that absorb incident infrared light of a specific frequency, i.e. chemical 
bonds which vibrational frequency is the same as the frequency of the incident radiation.  
The basic units of a FTIR spectrometer are shown in the Figure 23. The source 
generates the radiation, which then reaches the sample after being interfered on the 
interferometer. The detector records the interferogram of the beam passed through the 
sample. Then, having being intensified by the amplifier, the signal is converted to digital 
form. Finally, special computer software makes a Fourier transformation and presents the 
result of the analysis. Modern FTIR systems use the fast Fourier-transformation (FFT) 
algorithm, which performs faster analysis (56). 
 
Figure 23 – Basic units of FTIR spectrometer (56).  
The function of any kind of interferometer is based on the phenomenon of 
interference. Basically, the light beam spatially splits into two or more coherent beams. 
Each of the beams passes the different optical path and returns to the screen, creating an 
interference pattern. According to this pattern the phase displacement of the beams can 
be set. The most common interferometer used in FTIR is the interferometer designed by 
Albert Abraham Michelson (Figure 24). 
The principle of Michelson interferometer work can be described by the following 
steps: 
1. The light coming from the light source is divided by a semi-transparent beam 
splitter into two coherent beams. 
2. One beam is directed to a stationary mirror and reflected back from it on the 
beam splitter. 
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3. The other beam goes to a moving mirror and then it is also reflected back to 
the beam splitter. On the beam splitter both beams are recombined. 
4. These two coherent beams interfere with each other, due to the changes in 
the relative position of the moving mirror to the fixed mirror. Depending on the 
difference in the path between beams, they can either enhance or weaken 
each other. In the focal plane of the lens interference bands can be observed 
and recorded by the detector. 
5. Detector registers the intensity of the interferogram, which contains complete 
information about the spectral composition of the radiation coming from the 
source and passing through the sample. 
 
Figure 24 – Layout of the Michelson interferometer used for FTIR (57). 
If the sample absorbs the radiation with a certain frequency, the intensity of the 
interferogram will be decreased correspondingly to this frequency. After the Fourier 
transformation made on the computer, the resulting spectrum will show the absorption 
band of the sample.  
FTIR spectroscopy has some distinct advantages in comparison with other 
spectrometer techniques: 
 High resolving power and fast scanning. 
 Constant resolution over the whole spectral region. 
 High accuracy of the determination of the number of waves. 
 Possibility to study a wide spectral range during a single scanning. 
 Possibility to detect a weak signal. 
 Simple design with only one moving part (moving mirror). 
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 Powerful computers and software perform a wide possibility of processing 
with data apart from Fourier transform (baseline correction, smoothing, 
integration, library searching, etc.) (56,58-59). (56) (58) (59) 
The samples were powdered, mixed with KBr, and pressed as pellets. FTIR spectra 
were recorded at 48 scans with a resolution of 2 cm-1 (FTIR Mattson 7000).  
 
4.3.4. Gas adsorption: BET analysis.  
Solids can adsorb the condensable gases. The value of the adsorbed gas depends 
on the material of the solid and the nature of the gas. Significant influence in the 
adsorption phenomena that occurs on the solids is made by two factors: the surface area 
of a solid and its porosity. Thus, measuring the gas adsorption allows getting information 
about the specific surface area and pore structure of a sample. 
The BET analysis provides precise evaluation of a specific surface. The BET theory 
explains the adsorption of gas molecules on a sample surface. It was developed by 
Stephen Brunauer, Paul Emmett and Edward Teller in 1938. 
Being placed into the closed space filled with gas at certain pressure, sample starts to 
adsorb the gas. The mass of the sample increase and the pressure of the gas decreases. 
Later the pressure becomes constant and the sample mass stops increase. If the volume 
of the sample and the space, where it was placed, are known based on the pressure 
reduction and using ideal gas law the amount of the adsorbed gas can be calculated. The 
amount of the adsorbed gas will be proportional to the sample mass, the nature and the 
pressure of the gas and temperature (60-61). (60) (61) 
The measured volume of used gas at different pressure allows building adsorption 
isotherms. The shape of the isotherm describes the interaction between gas and sample. 
Depending on the type of the isotherm it is possible to make conclusion about the surface 
area and the porosity of the material. Figure 25 shows five possible types of isotherms. 
Type I isotherm is often called “pseudo-Langmuir isotherm” it is attributed mainly to 
microporous samples with relatively small surface. Type II is the most common isotherm 
obtaining during BET analysis. It is typical for non-porous or macroporous materials. The 
start point of the straight middle part of the isotherm is used for the relative pressure at 
which the monolayer adsorption is completed determination. Type III is relatively rare type 
of isotherms. It can be used for BET, since there is no asymptote in the curve, what 
means that monolayer was not formed. Type IV is associated with capillary condensation 
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in the pores, which is characterized by a larger slope at higher relative pressure. The initial 
part of the isotherm is similar to the type II and showed the formation of monolayer with 
following formation of multilayers. This type of isotherms is attributed to mesopores 
materials. Type V is a variety of type III isotherm when there are mesopores in sample. 
This type of isotherm is not applicable for BET analysis (60-61). (60) (61) 
   
Figure 25 – Types of isothermes (60). 
 Porous materials can be classified by the shape and size of pores. The IUPAC 
classification of pore size is following: micropores are pores with the size less than 2 nm; 
mesopores are pores between 2 and 50 nm; pores bigger than 50 nm are called 
macropores. The determination of pore shape can be done according the shape of 
hysteresis loop on the isotherm. Figure 26 presents 4 different types of hysteresis loops. 
(61) 
 
 
  Figure 26 – IUPAC classification of adsorption hysteresis loops (61). 
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Type H1 is usually attributed to the material with narrow distribution of relatively 
uniform pores. More complex network pore structures with not well-defined shape show 
H2 type adsorption hysteresis loop. H3 loop is observed with non-rigid aggregates of 
plate-like particles with slit-shaped pores. Type H4 is associated with samples containing 
meso- and micropores (61-62). (61) (62) 
BET is based on the kinetic model of adsorption processes, which was purposed by 
Langmuir. The most common equation describes BET is following: 
 
        
 
 
   
 
   
   
(
 
  
)  (9) 
 
Where Va – volume of adsorbed gas at pressure P; Vm – volume of adsorbed gas 
when surface is covered with a monolayer; P is saturation pressure; C is BET constant 
attributable to the energy of absorption in the first adsorbed layer (61-62). 
For an accurate measurement sample must be degassed (in vacuum) to remove 
water and other contaminants. After the sample is degassed it is moved into the analysis 
port (Figure 27), where it is cooled with liquid nitrogen. To measure gas adsorption low 
temperature must be maintained; thereby it will be rather strong interaction between gas 
molecules and sample surface. Afterwards the sample is removed from N2 atmosphere 
and heated to release and evaluate the amount of adsorbed gas. Final data is presented 
in the form of BET isotherms (the amount of adsorbed gas is a function of the relative 
pressure). The use of the obtained isotherms allows calculating total surface area. 
For BET analysis nitrogen is used, due to its strong interaction with a samples surface 
and its availability. Since helium it is not adsorbed by sample surface it is used for volume 
calibration of the sample cell (60). 
 
Figure 27 – Schematic layout of the BET instrument (60). 
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To evaluate the specific surface area and the average pore size the BET (Brunauer, 
Emmett and Teller) analysis (Micromeritics Gemini 2370 V5) was carried out and the 
obtained isotherms of adsorption/desorption nitrogen were analysed. 
4.3.5. UV-vis spectroscopy.  
Different types of molecules absorb a radiation with specific wavelength. UV-vis 
spectroscopy allows detecting the presence of chemical functional groups with valence 
electrons. The absorption of visible and ultraviolet (UV) radiations is associated with the 
excitation of electrons to higher energy states. This excitation of electrons to higher 
energy state is accompanied by the absorption of some amount of energy from the 
incident light which leads to decrease in intensity of light being transmitted. 
UV-Vis wavelength range generally corresponds to 200 – 1000 nm and therefore 
partly includes near infra-red (NIR). The limits of the range are determined by detectors 
and light sources as well as the materials brought into contact with radiation. Figure 28 
illustrates the basic structure of spectrophotometer. Electromagnetic radiation in UV-Vis 
range is generated by an appropriate light source. A good light source should produce 
sufficient energy or power. A monochromator disperses the light in order to select a 
narrow bandwidth as the incident radiation. Light dispersion, however, can be obtained by 
both gratings and prisms. The sample container, known as a cell or cuvette, is made of a 
transparent material. Some typical materials used are fused silica, quartz and glass. The 
sides of these cells should be highly polished to keep reflection and scatter losses to a 
minimum. Detectors collect the light transmitted from the sample and convert it into 
measurable current. The amount of produced current is proportional to the amount of light 
reaching the detector. Major detectors used are phototube, PMT, photodiode, photodiode 
array, CCD array etc. 
 
Figure 28 - Schematic layout of the UV- visible spectrophotometer (63). 
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The quantification of the released drug (dexamethasone, DEX) was made by UV-vis 
spectroscopy using a Shimadzu UV-3100 spectrophotometer linked to 2:10 UVProbe 
programme. The DEX concentration in each sample was calculated using a standard 
calibration curve (the curve was obtained previously with different DEX concentrations in 
PBS), relating the DEX concentration with the absorbance. A fresh medium of PBS was 
used as a reference during the analysis (64). 
4.4. Drug release experiments 
 
For an in vitro drug release experiment, a certain amount of DEX-loaded composite 
granules was loaded into a dialysis membrane tube and then added with 4 ml of PBS at 
pH=7.4. Afterwards the membrane was placed inside a conical flask with 200 ml of PBS at 
pH=7.4 (Figure 29). This system was then placed into the incubator hood (Buhler TH15) 
(Figure 30) at 37 °C and with a constant stirring (125 min-1). Aliquots of 4 ml of the 
supernatant liquid were taken periodically at different time intervals. An equal volume (4 
ml) of fresh PBS was added to the system every time after every aliquot withdrawal. The 
amount of the released DEX into the solution was measured by UV spectrometry 
(Shimadzu UV-3100 PC) at 241,5 nm. The concentration of the drug was calculated using 
a calibration curve (Appendix). 
 
 
Figure 29 – The scheme of the drug release experiment. 
PBS solution 
DEX loaded granules 
Dialysis membrane 
tube 
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To be used in the in vitro drug release experiment, the dialysis membrane tube 
requires pretreatment. For its protection the stock membrane is covered with glycerine, 
which must be removed before the use in the experiment. The cleaning was carried out 
according to the instruction (65): the membrane was heated at 80 °C for 30 min in the 
aqueous solution (800 ml) containing 2% sodium bicarbonate and 1 millimolar EDTA. 
 
Figure 30 – Incubator hood (Bühler TH15). 
4.5. Analysis of the morphology granules after drug release 
 
To analyse the change in the granules morphology, its degradation and swelling, a 
small amount of granules (2–5 mg) was immersed into different containers with 10 ml of 
PBS solution and kept at 37 °C. After different time intervals the granules were taken out 
from PBS solution, dried and analysed by SEM. The obtained SEM micrographs will be 
presented and discussed in the next chapter. 
4.6. Identification of the appropriate mathematical model 
 
According to the literature review the obtained results of drug release were compared 
with different mathematical models, using “DDSolver”, free software. “DDSolver” is a free 
Excel add-in software package, developed by Yong Zhang et al. for the analysis of drug 
dissolution data and fitting it to different models by using a nonlinear optimization method 
(66) Various mathematical models were chosen to fit the data and the best fit was 
selected. The conclusion on the mathematical appropriateness was made by comparing 
R2adj. (adjustment coefficient). 
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Results and discussions  
 
5.1 Physical and chemical characteristics of spray dried granules  
 
5.1.1. HAP and composite (HAP: CH) granules loaded with DEX 
 Figure 31 shows the SEM micrographs of the original commercial nanosized HAP 
particles (Figure 31(a)) and of the corresponding spray dried granules (Figure 31(b)). As 
observed spray drying allows to convert the initial HAP nanoparticles, which have an 
average size of  50nm, into uniform spherical granules with a diameter of few 
micrometres (Figure 31(b)). Moreover it is also noticed that HAP spray dried 
microspheres present a somewhat irregular and rough surface.  
 
 
Figure 31 – SEM micrographs of (a) commercial HAP from Fludinova and (b) spray dried HAP 
granules. 
In spite of their compact aspect the spray dried granules have a large specific 
surface area of 100m2/g (Table 6) which is comparable to that of the starting nanosized 
HAP particles (110m2/g) (Table 6). This indicates that the spray dried granules are 
porous granules that maintain the nanostructure of the starting HAP nanoparticles. 
Regarding the crystallinity of the spray dried granules it was noticed that spray 
drying did not modify the crystallinity of the initial particles. The X-ray diffractogram of 
initial HAP nanoparticles is presented in Figure 32. The X-ray diffraction pattern (XRD) of 
the HAP granules is presented in Figure 35 and it could be confirmed that the XRD of 
both materials, i.e. initial HAP particles and spray dried particles, were practically 
undistinguishable.  
b a 
        1µm      3µm 
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Figure 32 – XRD diffractogram of the starting HAP nanoparticles. 
Figure 33 allows comparing the EDS spectra of the initial HAP particles and of the 
spray dried granules. It is observed that Ca/P ratios corresponding to the initial HAP and 
spray dried granules are almost the same, i.e. 1,64 and 1,70, respectively, which is very 
close to the value of standard CA/P ratio in HAP – 1,67 (30). Since spray drying was 
carried out at 180 °C it is too low temperature to modify HAP. EDS allows to assume that 
stoichiometry of HAP was not changed  
  
 
Figure 33 – EDS spectra of: (a) commercial HAP from Fludinova and (b) spray dried HAP 
granules. 
Figure 34 shows the changes of morphology of spray dried granules as DEX and 
HAP nanoparticles are added chitosan to (CH) solution, for different HAP/CH ratios. 
Spray dried particles of CH+DEX (Figure 34(a)) can be described as particles of smooth 
surfaces with some concavities and an average size between 1,5 μm and 3 μm, though 
larger particles of chitosan 5-6 μm can be also observed. When HAP is also added to 
 
 
(a) (b) 
Universidade de Aveiro                                                            Results and discussion 
57 
 
the polymer solution, the spray-dried composite granules, i.e. CH:HAP [2:1]+DEX and 
CH:HAP [1:2]+DEX, show a tendency to lose their concavities and smooth surface thus 
acquiring a more spherical shape with a rougher surface as HAP/CH ratio increases. 
The granules of HAP+DEX composition (Figure 34(d)) have a spherical shape with 
rough surface and a size of 1-3 μm, being identical to the HAP granules. 
 
 
Figure 34 – SEM micrographs with different magnifications of spray dried granules with different 
HAP/CH ratio: (a) – CH+DEX; (b) – CH:HAP [2:1]+DEX; (c) – CH:HAP [1:2]+DEX; (d) – 
HAP+DEX 
In addition, it was also observed that the measured specific surface area (SSA) of 
the HAP+DEX granules was 114m2/g, being this a very close value to that of HAP 
granules (100m2/g).  
It may be thus concluded that the presence of DEX in the HAP particle suspension 
did not affect the morphology of HAP granules neither its nanostructured condition. 
Regarding the composite granules it was observed that their SSA decreases as the CH 
relative amount in the spray dried granules increases. Table 6 summarizes the SSA of 
the granules measured by gas adsorption using BET isotherm. 
Table 6 – Values of the specific surface area (SSA) of different types of spray dried 
granules. 
Composition of granules SSA 
Initial commercial HAP from Fludinova 110 m²/g 
HAP spray dried granules 100 m²/g 
HAP+DEX 114 m²/g 
HAP : CH (2:1) +DEX  93 m²/g 
1a 
2a 
1b 
2b 
1c 
2c 2d 
1d 
3 µm 
 
Universidade de Aveiro                                                            Results and discussion 
58 
 
HAP : CH (1:2) +DEX 10 m²/g 
HAP : CH (1:2) +DEX +Glutaraldehyde 52 m²/g 
Double spray-drying HAP:CH(1:2)+DEX 19 m²/g 
 
Regarding the crystallinity of spray dried (HAP+DEX) or of the composite 
(HAP:CH+DEX) granules which XRD patterns are presented in Figure 35, only the 
peaks corresponding to HAP are observed denoting that spray drying and/or the 
presence of DEX did not induce the formation of secondary calcium phosphate phases.  
 
Figure 35 – XRD patterns of different types spray dried granules. 
It is also noticed that with the decrease of HAP/CH ratio the HAP peaks become 
less prominent while the amorphous phase corresponding to CH becomes enhanced. 
The XRD of CH is shown in Figure 36 for a comparative purpose. 
Universidade de Aveiro                                                            Results and discussion 
59 
 
 
Figure 36 – XRD diffractogram of standard chitosan produced by Sigma Aldrich (67). 
Figure 37 shows the Fourier transform infrared (FTIR) spectra of HAP+DEX and of 
CH+DEX spray dried granules and a standard FTIR of DEX (68). 
The FTIR spectrum of HAP+DEX granules shows the characteristic bands of HAP at 
473, 558, 600, 1018 cm-1 which are attributed to bending vibration of PO4
3- group. Two 
peaks are also observed at 965 and 1087 cm-1 that corresponds to the stretching 
vibration of phosphate group. A broad peak around 3370 and a small peak 1662 cm-1 
are in the region where absorbed water is usually observed. A small peak at 3571 cm-1 is 
attributed to stretching vibration of OH- group. 
 
Figure 37 – FTIR spectra of (a) DEX (68), (b) CH+DEX and (c) HAP+DEX spray dried granules. 
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The spectrum of CH+DEX granules has a well-defined peak at 1025 cm-1 due to 
skeletal vibration of C-O stretching. The bands at around 895 and 1150 cm-1 are 
attributed to glycosidic bondings. The peak at 1320 cm-1 is characteristic of C-O-N 
stretching. The bands at 1380, 1410 and 2880 cm-1 indicate the presence of  -CH3, -CH2, 
and –CH groups respectively. N-H bending from amine and amide is indicated by the 
bands at 1555 and 1649 cm-1. The wave numbers of the peaks referred in the present 
work, the literature references and chemical bond peaks assignment are presented in 
the Table 7 (69-72). (69) (70) (71) (72) 
Due to overlapping of the main DEX peaks with some characteristic peaks of CH 
and HAP in the region of 1000-1100, 1500-1700 and 2900-3000 cm-1 it is difficult to 
detect DEX in the spectra of HAP+DEX and CH+DEX. However, it is possible to observe 
that the characteristic peaks in the regions of 1000 -1100 and 1500-1700 cm-1 are more 
intense for HAP+DEX and CH+DEX granules than for pure HAP and CH mentioned in 
literature (69). 
According to literature (73) the interaction between CH and DEX may be detected 
by the shift of characteristic peaks of CH (3250 cm-1) and DEX (3390 cm-1) to the wave 
numbers at 3286 and 3383 cm-1. In the present work the FTIR spectrum of CH+DEX 
presents a peak at 3286 and it is also possible to observe that the DEX peak lying at 
3390-3400cm-1 is shifted to 3350 cm-1 in the CH+DEX spectrum. This indicates that an 
effective interaction between the drug (DEX) and CH takes place. The spectra of the 
composite granules having different HAP/CH ratios are shown in Figure 38. In the same 
figure are also presented the spectra corresponding the granules cross-linked with 
glutaraldeide (GA) and to the double spray dried granules. It is generally observed that 
the FTIR profiles are similar in terms of the shape and intensity of its peaks. Comparing 
these spectra to those corresponding to (HAP+DEX) and to (CH+DEX), the bands 
around 1020, 1320-1410, 1555 cm-1 are wider and more intensive due to the overlapping 
of some characteristic peaks of both CH and HAP. 
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Figure 38 – FTIR spectra of spray dried granules with different (HAP/CH) ratio ((a) and (b)), 
cross-linked with GA (c) and double spray dried (d). 
Table 7 – Summary of FTIR analyses with peak interpretation. 
Wavenumber (cm-1) 
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Chemical bond description 
Reference 
(70-73) 
Present 
work 
470-472 ~473 + - + + + + PO4
3- bending vibration(HAP) 
565-568 ~558 + - + + + + PO4
3- bending vibration(HAP) 
602 ~600 + - + + + + PO4
3- bending vibration(HAP) 
897 ~895 + + + + + + glycosidic bonding 
962-964 ~965 + - + + + + PO4
3- stretching vibration 
1026 ~1025 - + 
+ + + + 
skeletal vibration of C-O 
stretching (CH) 
1036-1041 ~1018 + - PO4
3- bending vibration(HAP) 
1070 ~1065 - + - - - - C-O-C stretching (CH) 
1093 ~1087 + - - - - - 
PO4
3- stretching vibration 
(HAP) 
1150-1154 ~1150 - + + + + + 
antisymmetric stretching C-O-C 
and C-N stretching (CH) 
(glycosidic bonding) 
1320 ~1320 - + + + + + C-O-N stretching (CH) 
1375 ~1380 - + + + + + 
CH3 symmetrical deformation 
(CH) 
1414 ~1410 - + + + + + -CH2 bending vibration (CH) 
1584-1560 ~1555 - + + + + + 
N-H bending from amine and 
amide II (CH) 
1645 ~1649 - + 
+ + + + 
amide I (CH) 
1660 ~1662 + - absorbed water (HAP) 
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2864-2878 ~2880 - + + + + + C-H stretch (CH) 
3250 ~3286 - + + + + + 
O-H and N-H stretching 
vibration (CH) 
3390 ~3350 - + + + + + DEX and CH interaction 
3300-3400 ~3370 + - + + + + absorbed water (HAP) 
3571 ~3571 + - - - - - O-H stretching vibration (HAP) 
  
5.1.2. Cross-linked and double spray dried granules  
 
It was already mentioned that CH has a strong ability to swell (74). In order to 
improve the drug release the drug delivery system (DDS) was enhanced in the following 
way: to decrease the negative effect of CH swelling a cross linking agent, glutaraldehyde 
(GA) was used. Another attempt to improve the DDS was by carrying out a double spray 
drying step which was envisaged to promote a more effective encapsulation of the drug. 
The previous research carried out at the laboratory (75) showed that 0,2 wt% of GA is a 
sufficient amount of GA to cross link CH granules without inducing toxicity of the final 
product. One of the main requirements for good DDSs is to be non-toxic and not to 
promote harmful effects to the organism. It is also important that DDS degradation 
products are also non-toxic compounds to be easily excreted from the body without 
being accumulated. The components of the DDS studied in the present work are thought 
to fulfil these requirements.  
The morphology of cross linked HAP/CH granules is shown in the Figure 39. There 
is no significant difference as compared with the previously spray dried granules. As 
referred by S. G. Véronique Maquet, (76) the cross linking of CH does not change the 
morphology or size distribution of spray dried CH granules. 
  
Figure 39 – SEM micrographs of cross linked granules (HAP:CH[1:2]+DEX+0,2GA). 
The Figure 40 shows that the granules obtained by double spray drying present a 
core-shell like structure. The SEM micrographs (Figure 40(a)) illustrate the morphology 
of HAP+DEX granules produced during the 1st stage of spray drying. The shape and the 
3µm 
15µm 
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surface of these granules are very similar to that of the granules shown in the Figure 
34(d). Figure 40(d) presents the SEM micrographs of HAP:CH [1:2]+DEX produced 
during the 2nd stage of spray drying where  a lot of spherical 1,5 – 4 μm granules with a 
smooth surface are observed. Together with EDS spectrum (Figure 40(d)), that confirms 
the Ca/P presence, it is possible to make a conclusion that HAP+DEX particles during 
the 2nd stage of spray drying were covered with a CH layer.  
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Figure 40 – SEM micrographs and EDS spectra of double spray dried granules: (a) – 1st stage 
(HAP+DEX); (b) – 2nd stage (HAP:CH [1:2]+DEX); (c) – EDS of HAP+DEX granules; (d) – EDS 
of HAP:CH [1:2]+DEX granules. 
15µm 15µm 
3µm 3µm 
600nm 
1,5µm 
a 
a 
a 
b 
b 
b 
c d 
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5.2 Drug release experiments 
5.2.1 HAP and (HAP: CH) granules 
 
Figure 41 presents the cumulative drug release curves of 3 types of granules, i.e., 
HAP+DEX granules and composite granules with two different  HAP/CH ratios of [1:2]  
and [2:1]. As observed, in all the cases, the release curve presents an initial burst 
release followed by a much slower release rate that tends to a plateau where the release 
has almost stopped. In spite of these common features it may be pointed out that 
HAP:CH [1:2] presents the faster release as after 8 hours 80% of the drug is already 
released and the total amount of the DEX becomes released after nearly 50 hours. The 
other two release profiles which respect the HAP and HAP:CH [2:1] granules reach the 
plateau later on, i.e. approximately after 100 hours. The initial fast release of DEX 
exhibited by the three different types of granules indicates that DEX dissolution from the 
surface of the drug delivery systems (DDSs) is probably taking place. Also some part of 
the drug was probably encapsulated inside the granules during spray drying and may 
account for the slower drug release regime of the curves 
 
 
As referred previously, the granules HAP:CH [1:2] which have the larger amounts of 
CH are those with the lower SSA. It may be hypothesized that DEX exists predominantly 
at the granules surfaces and hence is rapidly released. In the case of the granules HAP 
Figure 41 – Cumulative drug release from granules: (Ж) – HAP+DEX; ( X) HAP+CH [1:2] +DEX,(▲) – 
HAP+CH [2:1] +DEX. 
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and HAP:CH[2:1] with a larger SSA and hence a larger porosity, it may be considered 
that the transport of DEX takes place from inner regions of the granules to the release 
medium and thus is a slower release process than that taking place from a surface 
region. This reasoning may explain the differences between the profiles of the last 
granules and that of HAP:CH [1:2] granules.  
5.2.2 Cross-linked and double spray dried granules  
 
Figure 42 compares the drug release profiles of composite granules having an 
HAP:CH ratio equal to [1:2], but produced in different manners: (i) in 1 spray drying 
stage without additional modification, (ii) cross linked with GA and (iii) in a double spray 
drying stage. It is observed that as compared to the non-modified granules the release 
profile from modified granules, i.e. from cross-linked and from double spray dried 
granules, takes longer to reach a plateau condition. This indicates an overall slower 
release rate of DEX in the case of the modified granules. For the particular case of cross 
linked granules and as compared to the non-cross linked system, the amount of released 
drug after 25 hours was lower, around 20% less. The retarding effect of cross linking in 
the drug release was also reported in literature: Y.Yan et al. (77) have mentioned that 
increasing the cross-linking degree increases the polymer density and by this way 
decreases the available free space for drug diffusion. Possibly this effect is also taking 
place in the cross-linked composite granules where DEX diffusion is made difficult by a 
denser polymer matrix. The variation of cross-linking degree by using different amounts 
of various cross-link agents is a promising issue for further studies, since it may open a 
wide range of possibilities to engineer the drug release rate. 
Regarding the release from the double spray dried DDS, it is observed that after an 
initial fast drug release, which is a typical feature observed in all the other DEX release 
patterns, a first plateau appears followed then by a second steep release that tends to a 
new plateau. This behaviour can be interpreted in the following way:  the first fast initial 
release accounts for the DEX existing at the surface of DDS. After the release of the 
superficial drug amount a plateau occurs indicating that temporarily no drug is available 
to be released. However prolonging the release time allows the swelling/erosion of the 
CH surface layer to take place which gives access to the drug encapsulated in the inner 
region of the granule; because of this a second fast release then occurs which evolves 
later to a second plateau.  
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Analyzing drug release patterns presented above in Figures 41-42, we can conclude 
that release of DEX can be enhanced by the drug carrier modification (varying ratio of 
HAP/CH, CH crosslinking, double spray drying). From the therapeutical point of view, 
HAP:CH[1:2]+DEX granules showed very fast release; after 25 h almost all drug was 
released. Since the idea of the present work is to study DDS for possible bone treatment 
applications, robust release is undesirable and attention should be directed to designing 
DDSs that provide prolonged release. However it is difficult to say why the pattern of 
HAP+DEX release in Figure 41 falls between that of HAP:CH[1:2]+DEX and 
HAP:CH[2:1]+DEX. It is possible to assume that the addition of CH disproportionally 
influence the drug release. Thus, the fastest release was observed for granules with the 
highest CH concentration. At the same time, HAP:CH[2:1]+DEX granules showed slower 
release than pure HAP granules loaded with DEX. The positive effect in this case could 
be explained by the presence of additional layer barrier of CH, which can work in a small 
manner to reduce the release rate. 
Figure 42 shows drug release from the granules with the same HAP/CH ratio [1:2]. 
This allows analysis of the impact of double spray drying and cross-linking. Since these 
granules contain around 60 % of CH, it is logical to compare their behavior with pure CH 
granules. According to the literature review (21-22,45),DDSs of the present work can be 
Figure 42 – Cumulative drug release from HAP:CH [1:2]+DEX granules: (Ж) – spray dried; (X) cross-
linked and spray dried,(▲) – double spray dried. 
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(21) (45) (22) categorized as diffusion-controlled matrix systems. The drug release for such types of 
DDS strongly depends on the swelling ability of the used polymer (21,45). (21) (45)  
In swelling controlled systems, upon particle contact with biological fluid, the 
polymer starts to swell. Within a short time of liquid penetrating the particle, the glass 
transition temperature of polymer is lowered due to relaxation of the polymer chains. 
Drug can diffuse out of the swollen rubber (21). 
Figure 42 allows the assumption that, in the studied system, drug release might 
occur in the same way described above. The fast release from HAP:CH[1:2]+DEX was 
replaced by more prolonged release for cross-linked granules. And double spray dried 
granules shows slower release even without cross-linking due to the probability that 
most of the drug was encapsulated inside the granule. In the outer CH layer the amount 
of DEX shouldn’t be high, since during 2 stage of spray drying in CH solution was 
immersed HAP+DEX granules. It means that CH can contain only DEX that was 
released from HAP+DEX microspheres during spray drying.  
Comparing the velocity of drug release in this research with (22), in which the drug 
release from spray dried CH microspheres (size from 2 to 10 µm) was studied, the burst 
release (less than 30-60 min for the all types of granules for 80-100% drug released) 
was observed by He et al. This is also attributed with some other papers (78) - spray-
dried non-crosslinked CH microparticles loaded with Scopolamine hydrobromide showed 
complete release after 1,5-2 hours. In both studies (22) and (78) there was mentioned 
that cross-linking allows to slightly slow down release. All these are correlated with the 
results of this research. Moreover, it helps to explain longer release observed in Figures 
41-42. Slower release from HAP/CH in comparison with the above mentioned releases 
for CH microspheres can be explained by the use of HAP. Taking into consideration all 
that was mentioned above the usage of HAP and CH allows to produce DDS with more 
prolonged time of drug release than when these components where used separately. 
Moreover, core-shell structure cross-linking and structuring showed good results for 
further improvement of drug release. 
5.2.3 Granules degradation during drug release  
To analyse the influence of PBS solution during the drug release experiment SEM 
micrographs of granules before immersing into PBS (Figure 43(1-2)) and after 24 h 
staying in PBS solution (Figure 43(3-4)) were compared. It is possible to observe that 
HAP+DEX granules maintained their shape. A little change in the surface, which looks 
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more rough as compared to the initial granules, can be explained by washing-out of 
small HAP particles during sample washing (washing was done to avoid the presence of 
crystals of the salts from PBS solution). Composite HAP:CH[1:2]+DEX and 
HAP:CH[2:1]+DEX granules show significant morphology changes. It is clear that the 
polymer after the drug release experiment did not maintain its original shape. This 
behaviour can be explained by the high swelling ability of CH.  
The morphology of double spray dried and cross-linked granules after 5 days 
release in PBS solution is shown in Figure 44. It may be observed that the changes in 
granules morphology are similar to the one observed in Figure 43. While the role of 
crosslinking cannot be observed in the SEM images alone, as the particle morphologies 
remain similar to those seen in Figure 43, the beneficial effect of crosslinking can be 
observed in Figure 42 showing the drug release curves. It was not observed the 
difference in morphology for cross-linked granules. However, the positive effect of was 
shown in Figure 42, where it clear that cross-linking allows to slow down drug release. 
Because of its swelling properties, CH does not maintain its morphology through the 
drug release process. The HAP particles, on the other hand, keep their structural 
properties. 
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Figure 43 – Granules morphology before (1-2) and after (3-4) drug release experiment (24h): (a) – HAP:CH [1:2] +DEX;(b) – HAP:CH [2:1] +DEX; (c) – 
HAP +DEX 
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Figure 44 – SEM micrographs of granules after 5 days of drug release experimente: (a) – double 
spray dried (HAP:CH[1:2]+DEX) and (b) – cross linked (HAP:CH[1:2]+DEX+0,2GA). 
5.2.4 Identification of the appropriate mathematical model 
 
Selecting an appropriate mathematical model to describe the drug release profile may 
allow to predict the effect of DDS modification (morphology composition of the granules) 
and to elucidate the mechanisms involved in the drug release process. In the following 
chapter four mathematical models were compared with the experimental drug release 
data. The evaluation of the convergence between the experimental data and the 
mathematical models was undertaken by comparing the R2adj. fitting coefficient (Figure 
46). The models where chosen based on their main features which are summarized in 
Table 8. 
Table 8 – Mathematical models selected for fitting the experimental DEX release data 
points. 
Mathematical 
model 
Equation  Main features of the model 
Higuchi F=kH*t^0.5 
- the 1st mathematical model used for 
drug release; 
- simple model; 
-  is“starting point” for many other models 
(79) 
Hixson-Crowell F=100*[1-(1-kHC*t)^3] indicated for : 
15µm 3µm 2µm 
15µm 3µm 
1a 2a 3a 
1b 2b 
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- spherical particles, which shape doesn’t 
change with time; 
- particles that remain intact and do not 
disintegrate into smaller fragments during 
dissolution 
Peppas-Shalin F=k1*t^m+k2*t^(2*m) 
- water penetrates in the polymer matrix 
and the polymer swelling takes place; 
- swelling creates a rubbery region, in 
which the drug diffusivity increases 
substantially. 
-during the swelling, two different states 
occur:  the glassy core and the gel layer 
(rubbery), exist in the polymer matrix 
Weibull F=Fmax*{1-Exp[-(t^β)/α]} - empirical model  
 
The Hixson-Crowell model was selected because it is recommended for spherical 
particles that maintain a stable morphology; this is the case of HAP+DEX granules which 
keep a constant spherical shape throughout the release period as previously referred and 
documented by Figure 43(c). Peppas model one of the commonly used for diffusion-
controlled systems (21). 
Weibull is an empirical model which was created to fit mathematically to the drug 
release curves regardless the nature of the DDS. And Higuchi model was chosen for 
comparison, as it is a simple model appropriate to describe a simple release process 
based on diffusion. 
The fitting of the various models to the different release curves was assisted by the 
software DDsolver. Figure 45 illustrates the fitting results respecting the (HAP+DEX) 
granules. 
Figure 46 compares the fitting parameter corresponding to the various DDSs and 
marthematical models under analysis. It is obvious that Weibul and  Peppas-Shalin model 
fit very well to all the drug release profiles with a fitting coefficient close to one. Higuchi 
model in spite of its simplicity does not apply to many of the DDSs; its best fit was 
obtained with the double spray dried granules. The poor result of Hixson-Crowell is 
correlated with Figures 43-44, since in Table 8 it is mentioned that this model describes 
DDSs wich spherical particles and size are staying the same during drug release.  
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Figure 45 – Comparison of theoretical mathematical model with experimental drug release data for 
HAP+DEX made with DDsolver. 
 
Figure 46 – Comparison of models appropriating to experimental data. 
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As it was shown by SEM analysis the size and morphology of DDS in present work was 
different after the drug release. 
Good fitting of Weibull model was expected, since it is empirical model. This model 
doesn’t have any parameter related with the intrinsic dissolution rate of the drug and there 
is no any y kinetic fundament. Weibull model can only describe, but doesn’t characterize 
the system (26). As it is mentioned by V. Papadopoulou in (80) that Weibul function can 
be used for kinetic release from a variety of DDSs, but it cannot “provide a hint for the 
release mechanisms of the drug in relation to the estimates of the Weibull parameters”.  
Shows one more time that Weibull model is appropriate for describing drug release, but 
not for identification the release mechanism, for example. However V. Papadopoulou in 
his work (80) was able to find some links between the values of empirical model constants 
and the diffusional mechanisms of the release. 
The main conclusion of so well fitting Peppas-Shalin model to obtained drug release 
patterns, proves one more time that assumption made after drug release curves were 
analysed is correct. The HAP/CH DDSs in present work be categorized as diffusion-
controlled systems and the drug release should be very similar and conform to the 
mechanisms described in this paper in 2.1.2. 
The choice of a mathematical model for developing DDS elucidating drug release 
mechanisms depends on the desired or required predictive ability and accuracy of the 
model. Sometimes the use of a simple empirical or semi-empirical model can be 
absolutely sufficient. However, when reliable, detailed information are required, more 
complex, mechanistic theories must be applied (81). 
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6. Conclusions and Recommendations 
 
This research studies the potential of HAP/CH microgranules for use in drug (DEX) 
incorporation and subsequent application as controlled release systems for this drug. The 
effects of the following parameters of granules preparation on the drug release behaviour 
were analysed: 
- the variation of HAP/CH ratio; 
- the effect of polymer crosslinking; 
- the effect of double spray drying; 
At the end of the work the obtained results were compared with different mathematical 
models and the best model was fitted to each composition of the DDS under study. 
 
The main conclusions withdrawn from the results obtained throughout this research can 
be summarized as follows: 
 Spray drying is a convenient technique for producing micro-sized composite 
(HAP/CH) granules. It allows getting homogeneous granules with controllable 
morphology. 
 The granules spray dried from the suspensions with different ratios of HAP/CH 
have different morphology. With increasing CH ratio the shape changes from the 
spherical granules with rough surface to particles with concavities and smooth 
surface. 
 Granules with CH:HAP [2:1]+DEX composition showed the most robust drug 
release (after 7h almost 80% of DEX was released) among all the other studied 
type of granules. 
 The cross-linking of CH has positive effect on drug release, Addition of 0,2 % of 
GA allowed to slow down the release of the drug. Due to the high swelling ability 
of CH it is necessary to use cross-link agents to prolong the drug release.  
 Double spray drying allowed producing core-shell structured granules, which 
showed even more prolonged DEX release. The two stepped release profile was 
observed, what can be explaining by the robust release of the drug from the 
surface during the 1st step and the following release of the drug from the internal 
part of the granules. From the results obtained when adjusting few mathematical 
models to the modulation of the results, it can be concluded that Peppas-Shalin 
and Weibull models are the most appropriate models for describing drug release 
for the all studied compositions of DDS. 
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 The results of drug release and mathematical modelling showed that HAP/CH 
DDS in present work can be attributed to diffusion-controlled systems.  
 
Recommendations for future work 
 
The results obtained in the present work revealed some needs of further studies aiming 
to clarify the following issues: 
1.  The evaluation of the drug distribution DDS may help better understand the 
mechanisms involved into the drug release and as a result the release can be 
controlled better. For the determination of DEX distribution in the solid state 
Dexamethasone Fluorescein (82) can be used with further Fluorescence Lifetime 
Imaging (FLIM) analysis or observation under a fluorescence microscope. (39) 
2. This research showed that producing core-shell structured granules by double-
spray drying is very sensitive to minor variations of the experimental conditions 
and thus require be repeating and studying in more detail. 
3. There is new generation of spray dryers (Mini Spray Dryer B-290 (83)) with 3-
fluids nozzles instead of 2-fluids, what allows producing core shell structured 
granules in one stage with high practical yield. Usage of such type of nozzles 
allows producing granules from two different solutions at the same time. Thus 
core-shell particles can be spray dried (there is even possibility to produce liquid 
core). The variation of feeding rates of two suspensions makes it possible to 
regulate thickness of the shell layer or the size of the core part;(85-86) (84) (85) 
4.  The further studying of the influence of the amount of the cross link agent on the 
drug release should be done. Different types of cross link agents might be used 
in experiment: low-toxic and natural compounds such as Genipin (77), TPP (86), 
etc.  
5. Since the pH at the nidus of inflammation might be different from the neutral, the 
drug release in buffer solutions with different pH (close to possible physiologic 
one) and the study of influence of pH on drug release rate should be carried out. 
6. Differential pulse voltammetry (DPV) and Square-wave adsorptive voltammetry 
(SW-AdsV) techniques can be used instead of UV-vis spectroscopy for the 
evaluation of released DEX. The advantages of these methods are: high 
detection (7.6·10-6 mol/L and 2.54·10-9 mol/L) and quantification limits (8.47·10-9 
mol/L); no need of taking different samples through different time interval – it 
allows to check the change of DEX concentration online. In both techniques 
hanging mercury drop electrode (HMDE) is used as the working electrode, 
Ag/AgCl as references electrode and platinum (for DVP) or graphite rode (for 
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SW-AdsV) as auxiliary electrode. Previously deaerated with nitrogen solution of 
DEX is cathodic scanned. The obtained polarogram (a plot of current against 
potential) contains oxidation/reduction loop with characteristic peaks. The 
intensity of these peaks is attributed to DEX concentration in the solution (87) 
(88). 
7. Biocompatibility test of researched DDS should be carried out in order to study 
the cell response. 
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APPENDIX 
Drug Release  
Standard Calibration Curve of DEX 
Standard curve was made by preparing DEX solution in several concentrations; such 
as 0.1, 0.2, 0.3, 0.5, 1.5, 2, 5, 8, 10 μg/mL in PBS solution. The absorbance was observed 
with UV-Vis spectroscopy and noted as follows: 
Table A1 - Absorbance of DEX solution in PBS 
DEX  μg/ml Absorbance 
0 0 
0.1 0.002 
0.2 0.004 
0.3 0.010 
0.5 0.021 
1.5 0.063 
2 0.075 
5 0.200 
8 0.320 
10 0.409 
 
From the absorbance data written above, curve was built and line equation was made, as 
shown in the figure below: 
  
 
Figure A1 - Standard calibration curve for DEX solution in PBS 
Based on the linear equation above, for one known absorbance (from UV-Vis 
spectroscopy), the concentration can be calculated as follows: 
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Drug release calculation: 
                                       
                                             
                                          
                                              
                   
  
 
      
             
                
                     
                         
Table A2 – Drug release (HAP+DEX) 
 
Time 
(min) 
Absorbance 
Dex 
Concentration 
in PBS(µg/ml) 
Drug 
released 
(µg) 
Drug 
released 
% 
0  0 0 0 0 
30 0.065 1.644 328.595 16.21 
45 0.083 2.086 423.622 20.90 
65 0.104 2.602 535.160 26.40 
90 0.126 3.143 653.676 32.25 
120 0.166 4.125 862.806 42.56 
150 0.169 4.199 894.049 44.11 
180 0.188 4.666 1004.212 49.54 
240 0.193 4.789 1047.445 51.67 
370 0.231 5.722 1253.332 61.83 
1260 0.280 6.926 1517.008 74.84 
1440 0.303 7.491 1657.735 81.78 
1800 0.283 7.000 1589.420 78.41 
4020 0.320 7.909 1799.239 88.76 
4320 0.328 8.106 1870.187 92.26 
5700 0.327 8.081 1897.696 93.62 
7050 0.342 8.450 2003.730 98.85 
7440 0.332 8.204 1988.388 98.09 
8460 0.327 8.081 1996.634 98.50 
8835 0.319 7.885 1989.646 98.15 
9960 0.309 7.639 1972.045 97.29 
10260 0.313 7.737 2022.256 99.76 
11400 0.287 7.098 1925.440 94.98 
11760 0.280 6.926 1919.435 94.69 
12900 0.289 7.147 1991.366 98.23 
